Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review

Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.